Pfizer (PFE) : Investors Asset Management Of Georgia Inc Ga Adv scooped up 195 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 13, 2016. The investment management firm now holds a total of 52,348 shares of Pfizer which is valued at $1,701,310.Pfizer makes up approximately 1.40% of Investors Asset Management Of Georgia Inc Ga Adv’s portfolio.
Pfizer opened for trading at $32.3 and hit $32.86 on the upside on Monday, eventually ending the session at $32.61, with a gain of 0.34% or 0.11 points. The heightened volatility saw the trading volume jump to 3,69,99,336 shares. Company has a market cap of $201,665 M.
Other Hedge Funds, Including , Tufton Capital Management sold out all of its stake in PFE during the most recent quarter. The investment firm sold 7,090 shares of PFE which is valued $230,425.Daiwa Sb Investments Ltd. reduced its stake in PFE by selling 23,129 shares or 59.47% in the most recent quarter. The Hedge Fund company now holds 15,760 shares of PFE which is valued at $512,200. Pfizer makes up approx 0.13% of Daiwa Sb Investments Ltd.’s portfolio.Needelman Asset Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 75 additional shares and now holds a total of 31,140 shares of Pfizer which is valued at $993,055. Pfizer makes up approx 2.92% of Needelman Asset Management Inc’s portfolio.Chelsea Counsel Co boosted its stake in PFE in the latest quarter, The investment management firm added 22,053 additional shares and now holds a total of 94,802 shares of Pfizer which is valued at $3,023,236. Pfizer makes up approx 0.88% of Chelsea Counsel Co’s portfolio.Nadler Financial Group boosted its stake in PFE in the latest quarter, The investment management firm added 27 additional shares and now holds a total of 29,661 shares of Pfizer which is valued at $945,889. Pfizer makes up approx 0.42% of Nadler Financial Group’s portfolio.
On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.